Kyverna Therapeutics, Inc. · NASDAQ:KYTX
Dr. Beth C. Seidenberg ("Seidenberg") reported a 7.80% stake in Kyverna Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 6, 2026
Dr. Beth C. Seidenberg ("Seidenberg") reported a 7.80% stake in Kyverna Therapeutics, Inc., 4,657,257 shares, as a passive investor on Dec 31, 2025. Filed Feb 6, 2026 (Schedule 13G/A).
- Stake
- 7.80%
- Shares
- 4,657,257
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Westlake BioPartners Fund I, L.P. ("Westlake Fund I") | 6.30% | 3,787,940 |
| Westlake BioPartners GP I, LLC ("Westlake GP I") | 6.30% | 3,787,940 |
| Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity Fund I") | 1.50% | 869,317 |
| Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I") | 1.50% | 869,317 |
| Dr. Beth C. Seidenberg ("Seidenberg") | 7.80% | 4,657,257 |
Source
Related
- Kyverna Therapeutics, Inc.
- Westlake BioPartners Fund I, L.P.
- Kyverna Therapeutics, Inc. shareholders
- Schedule 13G · Orin Hirschman · Oct 19, 2026
- Schedule 13G/A · Bain Capital Life Sciences Opportunities III, LP · Aug 14, 2026
- Schedule 13G · BlackRock, Inc. · Jul 29, 2026
- Form 4 · Clark Ian T · May 29, 2026
- Form 4 · Cohen Fred E · May 29, 2026